WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 315363
CAS#: 2062-78-4
Description: Pimozide (Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.
MedKoo Cat#: 315363
Name: Pimozide
CAS#: 2062-78-4
Chemical Formula: C28H29F2N3O
Exact Mass: 461.22787
Molecular Weight: 461.55
Elemental Analysis: C, 72.86; H, 6.33; F, 8.23; N, 9.10; O, 3.47
Synonym: R 6238; R-6238; R6238; Pimozide; Orap; Opiran.
IUPAC/Chemical Name: 1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
InChi Key: YVUQSNJEYSNKRX-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
SMILES Code: O=C1N(C2CCN(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)C5=CC=CC=C5N1
Appearance: White solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 461.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006996. Review. PubMed PMID: 19370666.
2: Rathbone J, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001949. Review. PubMed PMID: 17636692.
3: Lorenzo CR, Koo J. Pimozide in dermatologic practice: a comprehensive review.
Am J Clin Dermatol. 2004;5(5):339-49. Review. PubMed PMID: 15554735.
4: van Vloten WA. Pimozide: use in dermatology. Dermatol Online J. 2003 Mar;9(2):3. Review. PubMed PMID: 12639456.
5: Sultana A, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev. 2000;(3):CD001949. Review. Update in: Cochrane Database Syst Rev. 2007;(3):CD001949. PubMed PMID: 10908518.
6: Sultana A, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev. 2000;(2):CD001949. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD001949. PubMed PMID: 10796672.
7: Tueth MJ, Cheong JA. Clinical uses of pimozide. South Med J. 1993 Mar;86(3):344-9. Review. PubMed PMID: 8451677.
8: Opler LA, Feinberg SS. The role of pimozide in clinical psychiatry: a review.
J Clin Psychiatry. 1991 May;52(5):221-33. Review. PubMed PMID: 2033030.
9: Shapiro AK, Shapiro E, Fulop G. Pimozide treatment of tic and Tourette disorders. Pediatrics. 1987 Jun;79(6):1032-9. Review. PubMed PMID: 3295739.
10: Colvin CL, Tankanow RM. Pimozide: use in Tourette's syndrome. Drug Intell Clin Pharm. 1985 Jun;19(6):421-4. Review. PubMed PMID: 3891283.
